Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Takemura S, Shiomi S, Kinoshita H
Second Department of Surgery, Osaka City University Medical School, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
Gan To Kagaku Ryoho. 2001 Dec;28(13):1975-9.
The results of liver resection for hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) are affected by persistent active hepatitis and/or hepatic fibrosis including cirrhosis. In patients infected with HCV, interferon therapy prevents the development of HCC by eradication of HCV and/or the remission of active hepatitis. Although HCCs are found even in some patients treated with interferon, the results of liver resection for such HCCs were satisfactory, especially in patients successfully treated with interferon. Postoperative interferon-alpha therapy decreased recurrence after resection of HCV-related HCC in a randomized controlled trial. Strategies for viral infection as well as the carcinoma can improve the outcome after treatment of HCV-related HCC. Interferon therapy is useful to improve the outcome after treatments for HCV-related HCC.
丙型肝炎病毒(HCV)相关肝细胞癌(HCC)肝切除的结果受持续性活动性肝炎和/或包括肝硬化在内的肝纤维化影响。在感染HCV的患者中,干扰素治疗通过根除HCV和/或缓解活动性肝炎来预防HCC的发生。尽管在一些接受干扰素治疗的患者中也发现了HCC,但此类HCC肝切除的结果令人满意,尤其是在成功接受干扰素治疗的患者中。在一项随机对照试验中,术后α干扰素治疗降低了HCV相关HCC切除术后的复发率。针对病毒感染以及癌症的策略可以改善HCV相关HCC治疗后的结局。干扰素治疗有助于改善HCV相关HCC治疗后的结局。